S.Biomedics Co., Ltd. (KOSDAQ:304360)
South Korea flag South Korea · Delayed Price · Currency is KRW
20,350
-850 (-4.01%)
At close: Oct 22, 2026

S.Biomedics Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
16,49216,54813,73413,10812,1138,868
Revenue Growth
-3.53%20.49%4.77%8.22%36.59%66.72%
Gross Profit
8,1267,5476,7076,5546,1114,319
Operating Income
-11,284-8,344-5,442-5,989-3,752-4,628
Net Income
-12,058-8,122-6,691-10,321-6,327-5,667
Earnings Per Share
-992.32-684.07-581.66-944.09-619.09-558.24
EPS Growth
------

Revenue by Geography

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
South Korea
15,53715,8832,3521,8921,727920.03
Overseas
955.29664.711,38211,21610,3867,948
Total
16,49216,54813,73413,10812,1138,868

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
49,39714,66123,95010,6587,41912,881
Total Debt
20,17512,20514,16011,99513,7966,808
Net Cash (Debt)
29,2222,4569,790-1,337-6,3776,073
Net Cash Growth
2174.30%-74.91%----11.29%
Net Cash Per Share
2404.75206.86851.08-122.35-624.02598.26

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-7,113-3,981-3,500-6,149-3,205-3,287
Capital Expenditures
-4,035-4,604-1,390-1,847-9,295-474.49
Free Cash Flow
-11,148-8,584-4,890-7,996-12,501-3,762
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
49.27%45.61%48.84%50.00%50.45%48.70%
Operating Margin
-68.42%-50.42%-39.62%-45.69%-30.98%-52.19%
Pretax Margin
-62.98%-41.15%-41.92%-69.68%-43.01%-59.19%
Profit Margin
-73.11%-49.08%-48.72%-78.73%-52.23%-63.90%
FCF Margin
-67.59%-51.88%-35.61%-61.00%-103.20%-42.42%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
15.2827.4014.809.95--